CASRAI Dictionary

Tag: cancer research funding cuts

  • NIH Grant Termination Study: What the Data Show

    Independent tracking studies of the National Institutes of Health’s 2025 grant terminations show the cuts did not fall evenly across the biomedical research portfolio. This NIH grant termination study review of four separate tracking efforts finds early-career investigators, women-led projects, infectious-disease and health-equity research, and a small cluster of NIH institutes and institutions absorbed a disproportionate share of the losses.

    An NIH grant termination study, in this context, is an independent, data-driven analysis — built from crowd-sourced trackers such as Grant Witness and NIH’s own Research Portfolio Online Reporting Tools (RePORTER) — that quantifies which grants the agency cancelled and who held them, because NIH has not published a single consolidated breakdown of its own.

    How independent studies measured the terminations

    NIH has not released an official, comprehensive tally of terminated awards, so researchers and journalists have relied on independent trackers to reconstruct the picture. Four efforts now anchor most public analysis:

    • Fregolent et al. (2026), published in PNAS, matched the crowd-sourced Grant Witness database against NIH RePORTER records for grants cancelled between February and August 2025.
    • Patel, Liu and Jena (2025), published in JAMA Internal Medicine, linked NIH ExPORTER data with the HHS Tracking Accountability in Government Grants System for a narrower 28 February–8 April 2025 window.
    • The Association of American Medical Colleges (AAMC) published a running snapshot of terminations as of 5 May 2025.
    • A PubMed Central review (Faiman et al., 2025) tracked cumulative losses across the calendar year, including clinical-trial detail by disease area.

    Because each study samples a different date range and data source, the headline totals diverge — but the pattern of who was affected is remarkably consistent across all four.

    Which career stages absorbed the deepest cuts

    Training and early-career funding took a disproportionate hit. Under the PNAS analysis, women held 60% of the 530 cancelled grants among assistant professors and doctoral students, while men lost 59% of the 1,410 cancelled grants held by professors and associate professors — meaning losses skewed toward more junior investigators even as senior researchers lost more total dollars.

    Predoctoral and undergraduate pipeline awards were hit hardest of all: women held 58% of cancelled F31 and F30 predoctoral fellowships and 66% of cancelled T34 undergraduate research awards. NIH terminated $56.8 million across these early-career programmes and a further $329.6 million in T32 institutional training grants. Separately, the AAMC tracker found 29% of all terminated grants were research training or career-development awards, versus 61% classified as standard research-and-development grants — a training-pipeline share roughly double what its overall funding weight would predict.

    Which fields and institutes were hit hardest

    By institute, the National Institute of Mental Health recorded the highest number of terminations (128 grants), followed by the National Institute on Minority Health and Health Disparities (77 grants), according to the JAMA Internal Medicine analysis. By dollar value, the National Institute of Allergy and Infectious Diseases lost the most funding ($505.9 million), with NIMHD second ($223.6 million).

    Clinical-trial data tell a parallel story: infectious-disease trials were the most affected topic area, at 14.4% of active trials disrupted, compared with 2.2% for neurologic and reproductive-health trials. Prevention-focused trials lost funding at more than four times the rate of basic-science trials (8.4% versus 2.0%). A separate PubMed Central review tallied at least 160 disrupted clinical trials spanning cancer and HIV/AIDS research, within a cumulative $3.8 billion in terminated NIH funding tracked across 2025.

    Which institutions and regions felt the impact

    Terminations touched 210 recipient institutions, but concentration was high: Columbia University recorded the most terminations of any single institution (157 grants) in the JAMA Internal Medicine sample. Geographically, trials based in the Northeast US were terminated at 6.3%, the highest of any US region, while multiregional US trials saw none. International trials lost funding at a higher rate than domestic ones (5.8% versus 3.4%), suggesting non-US collaborators carried a heavier share of the disruption than US-only projects.

    How the four tracking studies compare

    Reading the totals side by side clarifies why headline figures vary so widely in news coverage — each study samples a different window and a different data source, not a different underlying event.

    Study Snapshot window Grants terminated Value tracked Distinct focus
    Fregolent et al., PNAS (2026) Feb–Aug 2025 2,291 terminated; 1,534 frozen $2.45 billion Gender and career-stage breakdown
    Patel et al., JAMA Intern Med (2025) 28 Feb–8 Apr 2025 694 $1.81 billion Clinical-trial disruption by institute, topic, region
    AAMC tracker As of 5 May 2025 777 $1.9 billion Grant-type split (research vs training)
    Faiman et al., PubMed Central (2025) Cumulative, 2025 160+ clinical trials $3.8 billion Disease-area detail (cancer, HIV/AIDS)

    Answer-first Q&A

    Which universities get the most NIH funding?

    Johns Hopkins University has historically led all US institutions in total NIH support, with other top recipients including the University of Washington, Stanford and the University of Michigan. Institutions with large NIH portfolios are not automatically those hit hardest by terminations — Columbia University topped the termination count despite not leading in total funding received.

    How much did the Trump administration cut from the NIH budget?

    The administration’s fiscal year 2026 budget request proposed a roughly 40% reduction to NIH’s overall budget, alongside the direct termination of thousands of active awards earlier in 2025. Congress has not enacted a cut of that scale, and litigation over specific terminations remains ongoing into 2026.

    Who is considered the biggest funder of biomedical research?

    NIH is the largest single public funder of biomedical and behavioural research in the world, with an annual budget exceeding $47 billion. That scale is why even a partial termination round — a few thousand of the roughly 50,000 active awards — produced measurable, trackable disruption across the sector.

    What this means for institutions and funders

    For research administrators, the consistent finding across all four studies is that training and early-career awards carry outsized termination risk relative to their share of total NIH spending. Institutions with concentrated early-career or health-equity portfolios should treat independent trackers such as Grant Witness and NIH RePORTER as live risk-monitoring tools, not just retrospective journalism sources, when advising principal investigators on contingency funding and bridge support.

    The divergence between studies also carries a methodological lesson for anyone citing termination figures: always state the snapshot date and data source alongside any total, since “NIH grant terminations” without a date range can mean anywhere from 694 to over 2,291 awards depending on which tracking effort is cited.

    Outlook: restoration, litigation and ongoing tracking

    Not all terminations have proved final. Litigation challenging terminations tied to diversity, equity and gender-related research topics has led to court-ordered reinstatement of some awards during 2025, and appeals continue into 2026. Independent trackers, including Grant Witness and the Impact Project, are continuing to log both new terminations and restorations, meaning the totals in this piece are a snapshot, not an endpoint.

    Researchers and administrators should expect further peer-reviewed analyses through 2026 as tracking teams extend their datasets — particularly on downstream effects for publications, collaborations and workforce retention, which the PNAS authors flag as their next research target. For institutions building sponsored-research risk frameworks, this body of independent tracking work is now a more reliable source than any single news report of the terminations themselves.

  • Research Funding Cuts in the UK: How Exposed Are Institutions to US Policy Shifts?

    British universities have spent 2026 absorbing two funding shocks at once. At home, UK Research and Innovation (UKRI) is mid-way through the biggest restructuring of its funding model since the body was created in 2017. Abroad, the US administration’s proposed reductions to federal science budgets have destabilised grant pipelines that many UK research groups quietly depend on. Research funding cuts in the UK are no longer a purely domestic story — they are increasingly a function of decisions taken in Washington, and institutions that have not mapped their transatlantic exposure are flying blind into 2027 planning cycles.

    The transatlantic funding shock: what changed in 2026

    On the UK side, the Department for Science, Innovation and Technology and UKRI confirmed in late 2025 how £38.6 billion of public R&D funding would be distributed over the following four years. The overall UKRI budget is set to rise towards £10 billion a year by 2030, but the distribution model has shifted to three “funding buckets”: curiosity-driven research, strategic government and societal priorities, and support for innovative companies — each intended to represent roughly half, a quarter and a quarter of spend respectively.

    That restructuring has not been smooth. In early 2026, three research councils — the Medical Research Council, the Biotechnology and Biological Sciences Research Council, and the Engineering and Physical Sciences Research Council — paused active grant routes. The Science and Technology Facilities Council separately confirmed it must find £162 million in cost reductions by 2029–30, driven by rising energy costs and unfavourable currency exchange rates, forcing project leaders to model cuts of 20%, 40% and even 60% to national facilities, particle physics and astronomy programmes. The House of Commons Science, Innovation and Technology Committee has since pressed UKRI’s chief executive for clearer, comparable data on the allocation changes.

    On the US side, the picture is starker still. The Association of American Universities has tracked administration proposals to cut federal research funding by 22% overall and basic research by 34% in a single fiscal year, with the Brennan Center for Justice estimating Congress was asked to strip an additional $44 billion from scientific research. The Center for American Progress estimates that National Institutes of Health (NIH) and National Science Foundation (NSF) cuts alone could cost the US economy $10–16 billion annually. Grant holds affecting Harvard and other institutions persisted well into 2026, with the NSF only lifting some holds in late May after sustained press scrutiny.

    How exposed are UK institutions to US funding shifts?

    The US is the UK’s single largest research collaborator by volume of co-authored output, and that collaboration runs through several distinct funding channels — each with a different risk profile. Institutions that treat “US exposure” as a single number miss where the real fragility sits.

    Exposure channel What is at risk 2026 signal UK mitigation lever
    Direct US federal co-funding Joint grants and sub-awards linked to NIH/NSF cycles NSF grant holds affecting Harvard and peer institutions persisted into May 2026 UKRI’s bucket reform reduces reliance on any single funding stream
    US philanthropic and foundation funding Foundation grants sensitive to the wider US fiscal and political climate US philanthropic sector under pressure to backfill federal shortfalls UK trusts, Horizon Europe association, and international co-funding
    Industry and corporate R&D partnerships Private R&D spend that tracks federal grant cycles US firms reassessing R&D allocation amid budget uncertainty UK government talent and relocation schemes attracting redirected private investment
    Talent pipeline Researchers on US-funded fellowships or joint appointments Early-career researchers facing contract non-renewal in the US UK schemes offering relocation funding for research teams

    Institutions with heavy involvement in biomedical, physics or environmental science co-funding arrangements are typically the most exposed, since these fields have historically carried the largest NIH and NSF footprints in joint UK-US work. Smaller specialist units embedded in a single US-funded programme carry proportionally more risk than large, diversified research portfolios — a distinction that should inform any institutional risk register.

    Answer-first: what researchers and administrators are asking

    Did research funding get cut?

    Yes, on both sides of the Atlantic. The UK’s Science and Technology Facilities Council confirmed £162 million in cost reductions by 2029–30, and three UKRI councils paused grant routes in early 2026. In the US, the administration proposed cutting overall federal research funding by 22% and basic research by 34% in a single fiscal year.

    Are universities getting less funding?

    Universities UK estimates that government policy decisions will reduce funding to English higher education providers by roughly £3.7 billion between 2024–25 and 2029–30. Combined with flat UKRI settlements and paused grant schemes, most English research-intensive institutions face a genuinely tighter funding environment than in the previous spending review period.

    Which UK universities are in financial trouble in 2026?

    The Office for Students has repeatedly flagged a growing minority of English providers running operating deficits, driven by falling international student income, domestic fee stagnation, and rising costs. This is a distinct pressure from research-specific council cuts, but the two compound: institutions under financial strain have less capacity to cushion research funding shocks internally.

    Why did Harvard get funding cut?

    Harvard University was among several US institutions to have NIH and NSF grants held or paused amid federal disputes over campus policy compliance. The NSF lifted some of these holds in May 2026 following media inquiries, but the episode illustrates how US federal research funding can be withdrawn on non-scientific grounds — a governance risk UK partners inherit indirectly through joint grants.

    UKRI’s own reforms as a partial buffer

    UKRI’s shift to a three-bucket funding model is contested — the Campaign for Science and Engineering has pushed UKRI for clearer year-on-year comparability, and the reform has coincided with disruptive grant pauses. But structurally, it offers UK institutions something the pre-2025 model did not: an explicit, published split between curiosity-driven research, strategic priorities, and innovation support, rather than allocation by historical research-council silos alone.

    • A published macro-level split (roughly 50% curiosity-led, 25% strategic priorities, 25% innovative companies) gives institutions a clearer basis for forecasting than opaque, council-by-council settlements.
    • UKRI has committed to providing high-level historical mapping so institutions can benchmark the new buckets against prior allocations.
    • The overall UKRI budget trajectory — rising toward £10 billion a year by 2030 — provides a growing (if unevenly distributed) domestic base that partially offsets US-side volatility, provided institutions position themselves across more than one bucket.

    None of this eliminates the pain of near-term grant pauses. But a funding architecture built around explicit strategic categories is inherently easier to diversify across than one built purely on discipline-specific council budgets — which is precisely the structural weakness that has made STFC-funded physics and astronomy groups disproportionately exposed to the current cuts.

    The case for diversification

    The practical lesson for institutional leaders is not to retreat from US collaboration — the scientific and reputational value of transatlantic partnerships remains real — but to stop treating single-source dependency as a manageable risk. UK government initiatives, including relocation-funded schemes aimed at researchers whose US positions have become uncertain, are a useful signal of where institutional and national strategy are converging, but they do not substitute for individual institutions actively rebalancing their own portfolios.

    • Map grant portfolios by funding channel (federal co-funding, philanthropic, industry, talent) rather than by discipline alone, so exposure is visible at the funding-source level, not just the subject level.
    • Treat Horizon Europe association and other multilateral schemes as genuine substitutes for at-risk US federal streams, not merely as supplementary income.
    • Build philanthropic and industry diversification into research strategy documents explicitly — the approach several research-intensive universities, including Cambridge, have already formalised.
    • Use grants management functions to track funder-level concentration risk as a standing item in institutional risk registers, not an ad hoc exercise triggered only after a funding shock.

    What this means for research administrators

    For research administration teams, the near-term task is unglamorous but essential: build an accurate, funder-level map of institutional exposure before the next funding cycle, not after it. That means treating grants management as a strategic function that sits alongside — not beneath — research strategy, with clear visibility into which grants, fellowships and facility partnerships sit on which side of the Atlantic.

    Longer term, the institutions that weather 2026’s funding turbulence best will likely be those that used UKRI’s bucket reform as an opportunity to rebalance rather than a bureaucratic inconvenience to endure. Diversification is not a hedge against any single government’s budget decisions — it is increasingly the baseline condition for research resilience.

    CASRAI’s work on the research administration function, including standards for describing contributor roles and institutional research infrastructure, sits alongside this diversification agenda — see the research administration resources, and browse funding and grants terminology in the CASRAI Dictionary.

  • University Research Funding Cuts: What the Court Cases Mean for Grant Recipients

    University research funding cuts have moved from budget-line disputes into federal courtrooms. Since April 2025, Harvard, Columbia and coalitions of state attorneys general have filed parallel legal challenges against the National Institutes of Health (NIH) and National Science Foundation (NSF) over grant terminations, funding freezes and new indirect-cost caps. The cases differ in posture — one produced a court ruling, one produced a settlement, others remain active — but together they are setting the procedural rules that will govern how frozen, denied or withdrawn grants get reviewed for years to come.

    For research offices, the practical question is no longer whether litigation is happening but what it is actually requiring agencies and institutions to do while cases proceed. This analysis sets out the pattern, compares the major tracks, and lists what sponsored-programs and general counsel offices should be monitoring now.

    The pattern: why universities are suing over federal funding

    Beginning in early 2025, the administration froze, terminated or delayed thousands of federal research awards to universities, citing diversity, equity and inclusion (DEI) content, alleged civil-rights failures, or new indirect-cost policy. According to a mapping analysis by the Center for American Progress, more than 4,000 grants across over 600 institutions were targeted for termination, with claimed award values between roughly $6.9 billion and $8.2 billion.

    Universities and state attorneys general responded with a consistent legal theory: that agencies violated the Administrative Procedure Act (APA) by acting in an “arbitrary and capricious” manner, skipping required notice-and-comment procedures, or exceeding authority Congress had granted them. In several cases, plaintiffs also raised First Amendment retaliation claims, arguing that funding was cut in response to institutional speech or governance decisions rather than for programmatic reasons.

    • Institutional suits — Harvard sued the federal government directly over a frozen $2.2 billion in grants and contracts.
    • Negotiated settlements — Columbia resolved its dispute through a financial and compliance agreement rather than litigating to judgment.
    • Multi-state actions — coalitions of state attorneys general sued NIH and NSF separately, challenging both DEI-related terminations and the NSF’s 15% indirect-cost cap.

    Harvard, Columbia and the multi-state track record

    The three tracks have produced different outcomes, which matters for institutions trying to predict what a given legal strategy is likely to achieve.

    Track Funding at stake Legal basis Outcome so far
    Harvard v. federal government ~$2.2 billion frozen (April 2025) APA “arbitrary and capricious”; First Amendment retaliation District court ruled the cuts unlawful (September 2025); the Department of Justice subsequently sued Harvard (March 2026) seeking to recoup funds and contest the ruling
    Columbia University ~$400 million cut (March 2025) Civil-rights compliance dispute; no APA suit litigated to judgment Settled for $221 million (July 2025) — $200 million civil-rights, $21 million employment claims; ~$400 million in research funding reinstated; increased federal oversight and reporting requirements
    Multi-state AGs v. NIH Hundreds of grants (DEI, transgender health, vaccine-hesitancy research) APA violations; exceeded statutory authority Settlement committed NIH to its “usual process” for grant review; a court separately ruled roughly 900 terminated grants unlawful and ordered reinstatement, though the administration has appealed
    Multi-state AGs (16 states) v. NSF STEM diversity programmes; 15% indirect-cost cap APA and constitutional claims regarding congressional intent Litigation ongoing; plaintiffs are seeking to block the indirect-cost cap and reverse related terminations

    Harvard’s case is the clearest judicial precedent to date: a U.S. District Court in Boston found the government’s cancellation unlawful and ordered funding restored, only for the Department of Justice to open a separate recoupment suit months later — a reminder that a favourable ruling does not end the underlying dispute. Columbia’s settlement, by contrast, traded a fixed financial payment and expanded oversight for the reinstatement of frozen funds without a court ruling on the merits.

    What the settlements and court orders have required so far

    Three concrete procedural requirements have emerged from this litigation, and they matter more to research administrators than the headline dollar figures:

    • NIH’s court-ordered grant review. Following the ruling that roughly 900 terminated grants were unlawfully cancelled, NIH was ordered to reinstate them and, in a related settlement, committed to returning to its “usual process” for reviewing applications rather than applying ad hoc political criteria.
    • Reinstatement is not automatic. Reporting has repeatedly noted that court-ordered reinstatements are not occurring uniformly across all affected grants or states, and that the administration has filed appeals that keep some awards in limbo even after a favourable ruling.
    • Settlements bundle funding with oversight. Columbia’s agreement did not simply restore money; it added federal reporting obligations on admissions and international-student data and required adoption of the IHRA definition of antisemitism — a template that later negotiations may echo.

    None of this activity has produced a single, uniform national standard. Each institution’s relief depends on its specific docket, its circuit, and whether it litigated to judgment or settled.

    Frequently asked questions

    Why did Harvard get its research funding cut?

    The administration froze roughly $2.2 billion in Harvard grants and contracts in April 2025, citing the university’s response to campus antisemitism concerns and its refusal to comply with a set of governance demands. Harvard sued, arguing the freeze violated the Administrative Procedure Act and the First Amendment.

    Why is Columbia University losing funding?

    Columbia had roughly $400 million in federal grants terminated in March 2025 over alleged civil-rights compliance failures related to campus antisemitism. Rather than litigate, Columbia negotiated a $221 million settlement in July 2025 that restored most of the frozen research funding in exchange for expanded federal oversight.

    Was terminated NIH research funding actually reinstated?

    Partially. A court ordered roughly 900 NIH grants reinstated after finding their termination unlawful, but subsequent reporting found reinstatement was inconsistent across institutions and states, and the administration has appealed the underlying ruling, leaving some awards unresolved.

    What should a research office track during active litigation?

    Research offices should track award status changes, agency guidance updates, court docket entries affecting their sponsors, and internal expenditure and indirect-cost documentation — the same records needed both for compliance and for supporting institutional legal counsel if a grant is challenged.

    What research offices should track while litigation is pending

    Regardless of whether an institution is a named party, sponsored-programs and research-administration offices with active NIH or NSF awards should maintain contemporaneous records across five areas:

    • Correspondence with program officers — emails, termination or stop-work notices, and summaries of calls, since these documents establish the factual record if an award is later challenged.
    • Award terms and modifications — particularly termination, suspension and indirect-cost clauses, which vary by grant vintage and mechanism.
    • Expenditure and indirect-cost documentation — detailed enough to substantiate negotiated facilities-and-administrative rates if a cap or clawback is contested.
    • Docket activity relevant to the sponsoring agency — court orders, appeals and settlement terms that could reinstate, further freeze, or attach new conditions to an award.
    • Contingency and bridge-funding plans — since even a favourable ruling can take months to translate into disbursed funds, as Harvard and NIH grantees have both experienced.

    Institutions should also coordinate closely with general counsel before responding to any new agency demand tied to a settlement template, since Columbia’s agreement shows that funding restoration can come bundled with reporting and governance conditions extending well beyond the original grants at issue.

    Implications and what comes next

    The litigation pattern suggests two durable lessons for institutional research offices. First, a court ruling in an institution’s favour does not guarantee funds will flow on the original schedule — reinstatement has proven uneven, and follow-on actions such as the Department of Justice’s suit against Harvard show that disputes can continue well after an initial win. Second, settlement and litigation are not mutually exclusive strategies within a single funding relationship: an institution can win a ruling on one set of terminated NIH awards while separately negotiating conditions with another agency, or facing new litigation over the same funds.

    For offices managing sponsored research and research administration more broadly, the operational takeaway is procedural discipline rather than prediction. Consult the CASRAI Dictionary for definitions of the compliance and funding terms surfacing in this litigation, and treat every termination notice, court order and settlement condition as part of a single evidentiary record — because in this funding environment, that record is what any given grant’s outcome will ultimately turn on.

  • mRNA Research Funding Cuts: Tracking the Institutional Fallout

    The 2026 research-funding landscape has a new, narrower fault line: mRNA research funding cuts tied specifically to the messenger-RNA vaccine platform, distinct from the broader reductions affecting cancer and biomedical research generally. On 5 August 2025, the US Department of Health and Human Services (HHS), under Secretary Robert F. Kennedy Jr., announced it was winding down mRNA vaccine development activities administered through the Biomedical Advanced Research and Development Authority (BARDA), terminating or restructuring 22 contracts worth nearly $500 million. Nearly a year on, the institutional fallout is now measurable, and research offices are adjusting their portfolios in response.

    What changed: HHS and BARDA’s mRNA wind-down

    The August 2025 announcement marked a deliberate shift in federal biomedical strategy: HHS stated it would move BARDA’s pandemic-preparedness investment away from mRNA platforms for respiratory viruses and toward what officials described as “safer, broader vaccine platforms.” The decision followed an earlier, separate cancellation of a roughly $600 million Moderna contract for a pandemic influenza mRNA vaccine in May 2025 — a move HHS and Moderna both describe as distinct from the August action, though the two together set the tone for the year’s mRNA-specific retrenchment.

    The August wind-down did not apply uniformly. According to contract-level reporting from HHS and trade press, the 22 affected awards fell into four categories:

    • Terminated contracts — awards cancelled outright, ending federal support for the specific project.
    • De-scoped work — existing contracts kept alive but with mRNA-specific tasks removed or reduced.
    • Rejected or withdrawn solicitations — proposals for new mRNA work that were declined before an award was made.
    • Restructured collaborations — joint projects renegotiated to change or remove the RNA component.

    Nature’s editorial board called the cancellations “the highest irresponsibility,” noting that a related executive order gives political appointees expanded authority over federal research-grant decisions — a governance change research offices should track independently of the funding total itself, since it affects how future awards in adjacent fields may be reviewed.

    Which institutions and companies have reported losses

    Public reporting to date identifies a specific set of universities, biotechs and pharmaceutical partners affected by the BARDA wind-down, each experiencing a different type of impact:

    Organisation Type of impact Project area
    Emory University Contract terminated Inhaled dry-powder mRNA antiviral platform
    Tiba Biotech Contract terminated RNA interference (RNAi) therapeutic — company disputes classification as an mRNA vaccine project
    Luminary Labs, ModeX, Seqirus Scope reduced mRNA-related tasks removed from existing BARDA agreements
    Pfizer, Sanofi Pasteur, CSL Seqirus, Gritstone Proposal rejected New mRNA-related solicitations declined pre-award
    AAHI, AstraZeneca, HDT Bio, Moderna/UTMB Collaboration restructured Nucleic-acid vaccine partnerships renegotiated

    Emory’s public statement was measured — a spokesperson said the university would “adjust as needed to pursue our research goals and ambitions” — but a lead researcher on the inhaled-platform project told local press the cuts risk signalling that mRNA is no longer a viable federal research priority, a concern echoed across the affected cohort.

    The scale of what is at stake extends well beyond the 22 terminated awards. A cross-sectional study published in JAMA Network Open, led by a team including researchers at Northwestern University and the University of Virginia, catalogued 178 active NIH grants related to RNA vaccines awarded between 1997 and 2025, representing $1.65 billion in cumulative federal investment. Those grants produced 2,342 publications and nearly 150,000 citations; 35% were cited in clinical trials or practice guidelines, and 18 were awarded through the Small Business Innovation Research and Small Business Technology Transfer programmes — the mechanism many university spinouts rely on to commercialise federally funded research. An accompanying commentary from researchers at the University of Calgary and University of Saskatchewan warned that excising RNA vaccine research from the NIH portfolio “is antithetical to current goals of making America healthy,” and separately noted that current-season flu vaccines are poorly matched to circulating strains — an argument for, not against, continued RNA platform investment.

    A Yale School of Public Health report has separately warned of downstream health consequences from the funding cancellation, and the American Lung Association and Harvard T.H. Chan School of Public Health have both published concern statements specifically about the loss of mRNA vaccine development capacity for respiratory disease.

    Common questions on the mRNA funding rollback

    Is the Moderna contract cancelled?

    Two separate Moderna contracts were affected. HHS cancelled a roughly $600 million bird-flu mRNA vaccine contract in May 2025, and Moderna’s collaboration with the University of Texas Medical Branch was restructured — not fully terminated — as part of the August 2025 BARDA wind-down.

    Why did the FDA reject Moderna’s mRNA flu vaccine application?

    The FDA said it refused to review Moderna’s mRNA flu vaccine filing because the company had not tested the product against a CDC-recommended comparator vaccine in a head-to-head clinical trial, as agency guidance issued in 2024 required — a regulatory, not funding, decision that compounds the platform’s commercial headwinds.

    How research offices are hedging portfolio risk

    Institutional research offices with active or pending mRNA-related awards are responding in broadly consistent ways, even where individual contract outcomes differ:

    • Diversifying platform exposure — reframing single-platform mRNA proposals as multi-modal nucleic-acid or protein-subunit programmes to reduce reliance on one federal funding line.
    • Pursuing non-federal co-funding — several affected groups, including Tiba Biotech, have publicly stated intent to pursue philanthropic, state-level, or industry funding to continue work federal contracts previously covered.
    • Auditing award language for termination clauses — sponsored-programmes offices are reviewing existing BARDA and NIH awards for early-termination-for-convenience language, which was the operative mechanism in several August 2025 cancellations.
    • Separating cancer-mRNA and infectious-disease-mRNA portfolios — because the HHS wind-down targeted respiratory-virus vaccine platforms specifically, institutions with mRNA cancer-vaccine work are treating that portfolio as distinct in risk profile, even though it uses overlapping delivery technology.

    For research administration offices, this is a live case study in sponsor-concentration risk — the same principle that underpins diversified grant portfolios more broadly. Institutions tracking these developments alongside broader shifts in research administration practice are better positioned to model exposure across single-sponsor dependencies before the next policy shift, rather than after.

    Outlook: what research administrators should track next

    The mRNA-specific rollback is narrower than the broader federal research-funding contraction affecting NIH and cancer research overall, but its concentration in a single platform and a single agency relationship (HHS/BARDA) makes it a useful, contained case study in how quickly a funding line can be repriced on policy grounds rather than scientific merit. Three signals are worth monitoring going into the next budget cycle: whether the executive order expanding political appointee authority over grant decisions is applied beyond mRNA to other platforms; whether the $1.65 billion NIH RNA-vaccine grant base identified in the JAMA Network Open study sees further reductions at renewal; and whether affected institutions successfully replace lost BARDA funding with non-federal sources, which would signal a durable shift in how pandemic-preparedness research is financed. Research offices with mRNA-adjacent portfolios should treat this episode as a template for stress-testing single-sponsor concentration risk across all federally funded platforms, not just this one.

  • Cancer Research Funding Cuts: What the 2026 NIH Data Shows

    Search interest in cancer research funding cuts has spiked through the first half of 2026, tracking a wave of NIH award terminations, a proposed 37% cut to the National Cancer Institute’s budget, and a roughly $500 million rollback of federal mRNA vaccine research contracts. For research administrators, the practical question is no longer whether the funding landscape has shifted — it clearly has — but how exposed a given portfolio is, and what a grants office can do about it before the next termination notice arrives.

    What the 2026 NIH Funding-Cut Data Shows

    HHS reporting released in April 2026 puts the cumulative tally of terminated National Institutes of Health awards at 1,392, with $539 million in unliquidated obligations still outstanding — funds that were committed but not yet disbursed when the terminations took effect. That figure sits alongside an earlier, broader accounting: a PubMed Central analysis found that by June 2025, roughly 2,300 NIH grants worth nearly $3.8 billion had already been cancelled agency-wide, including more than 160 cancer-related clinical trials.

    The cuts are not evenly distributed across the calendar. A May 2025 US Senate HELP Committee Minority Staff report found the administration cut approximately $2.7 billion in NIH funding during the first three months of 2025 alone, with cancer-specific research funding down 31% for that quarter compared with the same period in 2024. On the budget side, the National Cancer Institute’s own FY2026 congressional justification requested $4.53 billion — a $2.69 billion, or 37.3%, reduction from its FY2025 level of $7.22 billion.

    • Indirect cost cap: facilities-and-administrative (F&A) reimbursement rates on NIH grants have been capped at 15%, cutting into the overhead that funds shared cores, compliance staff, and research infrastructure at host institutions.
    • mRNA-specific rollback: HHS cancelled roughly $500 million in mRNA vaccine and therapeutics research contracts during 2025, with direct knock-on effects for mRNA-based cancer immunotherapy pipelines.
    • Review bottlenecks: reporting in early 2026 described new layers of administrative review delaying disbursement of already-approved grants, with some applications flagged for specific terminology before release.

    Which Disease Areas and Grant Types Are Most Exposed

    Exposure is not uniform across tumour types. A 2025 analysis of NIH and Congressionally Directed Medical Research Programs (CDMRP) funding from 2013 to 2022, presented at the Journal of Clinical Oncology, found that funding levels correlate strongly with disease incidence (Pearson coefficient 0.85) but only weakly with mortality (Pearson coefficient 0.36) — meaning historically under-funded, high-mortality cancers have the least financial cushion to absorb further cuts.

    Cancer type Combined NIH + CDMRP funding, 2013–2022 Relative funding position
    Breast $8.36 billion Highest-funded
    Lung $3.83 billion Well-funded
    Prostate $3.61 billion Well-funded
    Hepatobiliary $1.13 billion Under-funded vs. mortality burden
    Cervical $1.12 billion Under-funded vs. mortality burden
    Uterine $435 million Lowest-funded

    Grant type matters as much as disease area. Early-stage-investigator R01s, K-series career development awards, and T32 institutional training grants have been disproportionately represented among terminations, largely because diversity, equity, and inclusion-linked language in aims or personnel sections triggered policy-based review flags. Multi-year, non-competing renewals and diversity supplement awards have also recurred repeatedly in termination letters reviewed by health-policy reporters. Large P30 cancer-centre support grants are separately exposed through the F&A cap, since their budgets rely heavily on indirect-cost recovery to fund shared facilities.

    Answer-First Q&A: Cancer Research Funding Cuts

    Why is NIH cutting cancer research funding?

    The terminations stem from a mix of executive-branch policy priorities — including the rollback of diversity, equity, and inclusion-linked research — and proposed budget reductions for FY2026 and FY2027. Congress has historically restored some NIH funding after similar proposals, but administrative terminations of already-awarded grants have proceeded independently of the appropriations process.

    How much cancer research funding has been cut?

    By April 2026, HHS reporting recorded 1,392 terminated NIH awards with $539 million in unliquidated obligations. Separately, cancer-specific funding fell 31% in the first quarter of 2025 versus the prior year, and the National Cancer Institute’s FY2026 budget request represents a 37.3% reduction from its FY2025 level.

    Which cancer types are most affected by funding cuts?

    Historically under-funded cancers with high mortality — including uterine, cervical, and hepatobiliary cancers — have the least buffer to absorb cuts, since funding has tracked incidence rather than mortality. Early-career researchers and training-grant recipients across all disease areas are also disproportionately exposed.

    What Grants Offices Can Do Now

    None of this is speculative risk anymore — it is portfolio management. Institutions with active NIH-funded cancer research should treat funding volatility as a standing operational condition rather than a one-off shock, and research administration offices should build response capacity accordingly.

    • Bridge funding: establish or expand an internal bridge-fund mechanism, paired with external bridge grants from bodies such as the American Association for Cancer Research and the American Cancer Society, to keep terminated projects and personnel intact for six to twelve months while alternative funding is secured.
    • Appeals and documentation: maintain a standing file of scientific-merit documentation for every active award so a formal reconsideration request — or, where warranted, legal challenge — can be filed quickly; several 2025 terminations were reversed after litigation established that cancellations lacked adequate scientific justification.
    • Diversified funder mix: reduce single-funder concentration risk by cultivating relationships with disease-specific foundations (for example, the V Foundation and Damon Runyon Cancer Research Foundation), state-level programmes such as Texas’s CPRIT, and international co-funding arrangements, rather than relying on NIH as the sole primary sponsor for a given research line.
    • F&A exposure modelling: run budget scenarios against the 15% indirect-cost cap now, before it applies at renewal, so cancer-centre and core-facility budgets are not caught unprepared.
    • Track funding-notice guidance: assign a named staff member to monitor NIH Notice of Funding Opportunity and Guide Notices for terminology or eligibility changes that could flag active or pending applications for review.

    Professional associations — including ARMA, NCURA, and INORMS — have begun circulating shared templates and peer intelligence on termination response, and grants offices that pool this knowledge across institutions are responding faster than those working in isolation. As the FY2027 budget cycle approaches, with a further proposed reduction to overall NIH funding under discussion in Congress, the institutions best placed to protect their cancer research portfolios will be those that treated 2025’s cuts as a stress test rather than a one-time event — and built the bridge-funding, appeals, and diversification infrastructure needed to withstand the next round.